Zobrazeno 1 - 10
of 321
pro vyhledávání: '"P C, Limburg"'
Autor:
Fleur Schaper, Mirjan M van Timmeren, Arjen Petersen, Gerda Horst, Marc Bijl, Pieter C Limburg, Johanna Westra, Peter Heeringa
Publikováno v:
Molecular Medicine, Vol 22, Iss 1, Pp 12-21 (2016)
Abstract High mobility group box 1 (HMGB1) is a nuclear DNA binding protein that acts as an alarmin when secreted. HMGB1 is increased in systemic lupus erythematosus and might represent a potential therapeutic target. We investigated whether treatmen
Externí odkaz:
https://doaj.org/article/e7ed838ff5194e5cb636f3232ac5e2f6
Autor:
Alexandre W S de Souza, Karina de Leeuw, Mirjan M van Timmeren, Pieter C Limburg, Coen A Stegeman, Marc Bijl, Johanna Westra, Cees G M Kallenberg
Publikováno v:
PLoS ONE, Vol 9, Iss 4, p e96067 (2014)
The objective of this study was to evaluate whether levels of high mobility group box 1 (HMGB1) in granulomatosis with polyangiitis (GPA) patients are associated with carotid atherosclerosis, related to levels of soluble receptor for advanced glycati
Externí odkaz:
https://doaj.org/article/ef4d3b06dcd5456aba006eafdccaeba4
Autor:
Jose Stam, Wayel Abdulahad, Minke G Huitema, Caroline Roozendaal, Pieter C Limburg, Margriet van Stuijvenberg, Elisabeth H Schölvinck
Publikováno v:
PLoS ONE, Vol 6, Iss 10, p e25690 (2011)
Fluorescent Cell Barcoding (FCB) is a flow cytometric technique which has been used for assessing signaling proteins. This FCB technique has the potential to be applied in other multiparameter analyses. Since data on antigen (Ag)-specific T-cell immu
Externí odkaz:
https://doaj.org/article/bdd5bdab48c44630a63d46013497a67b
Publikováno v:
Methods in molecular biology (Clifton, N.J.). 1901
ANCA testing was introduced in many laboratories throughout the world when it was recognized that a significant subset of patients with small vessel vasculopathies presented with such antibodies. Many laboratories developed and introduced in-house te
Autor:
J. W. Cohen Tervaert, R. Goldschmeding, J. D. Elema, P. C. Limburg, M. van der Giessen, M. G. Huitema, M. I. Koolen, R. J. Hené, T. H. The, G. K. van der Hem, A. E. G. Kr. von dem Borne, C. G. M. Kallenberg
Publikováno v:
ARTHRITIS AND RHEUMATISM, 33(8), 1264-1272. John Wiley and Sons Inc.
Antineutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase (MPO) were found in 53 patient sera that were routinely submitted for antineutrophil cytoplasmic antibody determination. Based on clinical and histologic criteria, 15 of t
Publikováno v:
Gut. 38:348-354
The bacterial flora in the human colon, although extremely diverse, has a relatively stable composition and non-infectious anaerobic bacteria are dominant. The flora forms a pool of numerous different antigens separated from mucosal immunocompetent c
Autor:
M M, van Gameren, P H, Willemse, N H, Mulder, P C, Limburg, H J, Groen, E, Vellenga, E G, de Vries
Publikováno v:
Blood. 84:1434-1441
To define the toxicity profile of recombinant human interleukin-6 (rhIL- 6) and to study its effect on hematopoiesis, biochemical parameters and other cytokines, rhIL-6 was administered in a phase I-II study to 20 patients with breast carcinoma or no
Publikováno v:
Cytometry. 16:270-279
We describe a flow cytometry method for analysis of noncultured anaerobic bacteria present in human fecal suspensions. Nonbacterial fecal compounds, bacterial fragments, and large aggregates could be discriminated from bacteria by staining with propi
Autor:
E, Brouwer, A S H, Gouw, M D, Posthumus, M A, van Leeuwen, A L, Boerboom, J, Bijzet, R, Bos, P C, Limburg, C G M, Kallenberg, J, Westra
Publikováno v:
Clinical and experimental rheumatology. 27(6)
Despite the important role of the transcription factor HIF-1alpha in angiogenesis and inflammation, only a few studies on HIF-1alpha expression have been performed in RA patients. The aim of the present study was to identify the layer in synovial tis
Autor:
S, Arends, H R, Lebbink, A, Spoorenberg, L B, Bungener, C, Roozendaal, E, van der Veer, P M, Houtman, E N, Griep, P C, Limburg, C G M, Kallenberg, G J, Wolbink, E, Brouwer
Publikováno v:
Clinical and experimental rheumatology. 28(5)
To investigate the influence of antibody formation to TNF-α blocking agents on the clinical response in AS patients treated with infliximab (IFX), etanercept (ETA), or adalimumab (ADA), and to investigate the development of ANA, ANCA, and anti-dsDNA